FINCH THERAPEUTICS GROUP INC (FNCH)
US31773D2009 - Common Stock
FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023
Finch Therapeutics Gr just reported results for the fourth quarter of 2023.
FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finch Therapeutics Gr (NASDAQ:FNCH) just reported results for the fourth quarte...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday!
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start off the day right with a dive into the biggest pre-market stock movers worth watching on Tuesday morning!
Finch announces reverse stock split to regain Nasdaq compliance (NASDAQ:FNCH)
Finch Therapeutics (FNCH) will effect a one-for-30 reverse stock split of its issued and outstanding common stock, effective opening of trading on June 12, The reverse stock split...
Finch Announces Reverse Stock Split of Common Stock
Finch Announces Reverse Stock Split of Common Stock
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome...
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a...
Finch Therapeutics brings on Roivant Sciences' Matthew Blischak as CEO (NASDAQ:FNCH)
Finch Therapeutics (FNCH) on Tuesday said it had appointed Matthew Blischak as CEO, effective May 16. Read more on the executive change here.
Finch Therapeutics Announces Executive Leadership Transitions
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with the biggest pre-market stock movers that traders will want to keep an eye on for Monday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with an overview of all the biggest pre-market stock movers worth watching on Thursday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers traders will want to know about on Wednesday morning!
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday!
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a...
Finch stock rises despite abandoning phase 3 trial, cutting ~95% workforce
Finch Therapeutics (FNCH) is discontinuing a phase 3 trial of its bacterial infection drug CP101 and reducing workforce by ~95%.The company noted that it will discontinue the...
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH)...